Cormorant Asset Management LP Sells 600,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Cormorant Asset Management LP lowered its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 31.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,325,000 shares of the company’s stock after selling 600,000 shares during the quarter. Centessa Pharmaceuticals makes up 1.5% of Cormorant Asset Management LP’s holdings, making the stock its 16th biggest position. Cormorant Asset Management LP’s holdings in Centessa Pharmaceuticals were worth $33,138,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CNTA. Avoro Capital Advisors LLC grew its position in Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares during the last quarter. Braidwell LP bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at $54,730,000. Maverick Capital Ltd. bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at $41,110,000. Adage Capital Partners GP L.L.C. grew its position in Centessa Pharmaceuticals by 20.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after acquiring an additional 1,449,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Centessa Pharmaceuticals in the 2nd quarter valued at $16,052,000. Institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling

In other news, insider Karen M. Anderson sold 41,076 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Trading Up 0.3%

Centessa Pharmaceuticals stock opened at $39.87 on Thursday. The stock has a 50-day moving average of $39.65 and a two-hundred day moving average of $31.11. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.30 and a one year high of $40.26. The stock has a market cap of $6.17 billion, a PE ratio of -22.27 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Analysts Set New Price Targets

CNTA has been the topic of a number of recent research reports. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Hold” and an average price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.